Abstract
No public abstract is available from the verified source records.
Sarra Laabidi, Amal Hajlaoui, Maissa Abbes, Tayssir Ben Achour, Mariem Tabka, Donia Gouiaa, Fatma Said, Sahar Chtioui, Safa Rahmouni, Khaoula Zouaoui, Soumaya Boussaid, Sonia Rekik, Nadia Ben Mustapha, Mariem Serghini, Mourad Mokni, Hela Sahli, Asma Labidi, Monia Fekih
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The changing face of rheumatoid arthritis therapy: results of serial surveys
10.1002/1529-0131(200002)43:2<464::aid-anr30>3.0.co;2-u · 2000
6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease
10.1097/00042737-200012110-00010 · 2000
Methotrexate in the treatment of arthritis and connective tissue diseases
10.3949/ccjm.54.4.327 · 1987
Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation
2006
Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?
10.1046/j.1365-2036.2004.01819.x · 2004
Methotrexate and histologic hepatic abnormalities: a meta-analysis
10.1016/s0002-9343(05)80060-9 · 1991
Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy
10.2340/0001555572361364 · 1992
Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study
10.1016/j.jhep.2010.04.043 · 2010
Associated factors with liver fibrosis in rheumatoid arthritis patients treated with methotrexate
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1007/s10067-023-06847-7 · 2024
Risk of liver fibrosis in methotrexate-treated patients: a systematic review
2022
A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn’s disease receiving methotrexate therapy
2020
Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial
10.3109/00365521.2011.647412 · 2012
Prevalence of liver fibrosis by Fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis
10.1007/s10067-021-05678-8 · 2021
Unresolved referenced work
Kept as external metadata until matched
Use of the EvalObs® adherence scale in an unselected French population of treated subjects with antihypertensive, hypolipemiants or oral antidiabetics medications: the FLAHS 2017 adherence survey
10.1016/j.ancard.2018.05.002 · 2018
High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS)
10.1186/s42358-020-00145-5 · 2020
Methotrexate-induced hepatic injury in an adult. A case report
10.1001/archinte.1964.00280080027006 · 1964
Hepatic fibrosis and Cancer: the silent threats of metabolic syndrome
10.4093/dmj.2023.0240 · 2024
Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists
10.1136/ard.55.5.273 · 1996
Monitoring methotrexate toxicity in juvenile idiopathic arthritis
10.3899/jrheum.090482 · 2009
Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury
10.1046/j.1440-1746.2001.02644.x · 2001
EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update
10.1016/j.jhep.2021.05.025 · 2021
Noninvasive methods for assessing liver fibrosis and steatosis
2024
Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate
10.1136/annrheumdis-2016-210629 · 2017
Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus
2008
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis
10.1016/j.jhep.2009.06.008 · 2009
Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated
10.1016/j.jhep.2022.12.034 · 2023
Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis
10.1016/j.alcohol.2004.07.008 · 2004
The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment
10.1001/archderm.1989.01670210056007 · 1989
Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines
10.1371/journal.pone.0194401 · 2018
Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy
10.1093/rheumatology/kep023 · 2009
Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial
10.1002/art.20167 · 2004
A novel panel of blood markers to assess the degree of liver fibrosis
10.1002/hep.20935 · 2005
Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment
10.1016/j.jhep.2007.01.024 · 2007
Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients
10.1111/dth.15203 · 2022
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
10.1016/j.jaad.2009.03.027 · 2009
No additional external references are available.